SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Mocha Jet, Drugdoctor, RizZo, lasers, John_Langston, IB_
Search This Board:
Last Post: 8/4/2015 10:20:52 PM - Followers: 684 - Board type: Free - Posts Today: 0

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

Elite’s website can be found by going to

How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.


Recent Press Releases:

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200

Apr 21, 2015
Elite Pharmaceuticals Announces Launch Of Generic Hydroxyzine Tablets

Feb 17, 2015
Elite Pharmaceuticals Provides Guidance On Phase III Study For ELI-200

Jan, 15 2015
Elite Pharmaceuticals Announces First Shipment Of Generic Isradipine Capsules

More information can be found by going to Elite’s investor section:
Highlights From Last Quarter:

Third Quarter ending December 31, 2014
♦  Consolidated revenues for the third quarter of Fiscal 2015 continued their upward trend, rising to $1.4 million, an increase of approximately 8.5% over consolidated revenues for the second quarter of Fiscal 2015. The third quarter revenues for this year were $0.3 million below revenues reported for the third quarter of the prior fiscal year due to a one-time $0.6 million milestone that occurred in the prior year third quarter. Development of our proprietary abuse-deterrent opioid technology continues to be Elite's top priority. During the quarter, Elite invested an additional $2.3 million in clinical trials and other product development activities.

Highlights for the third quarter
♦  As of December 31, our working capital was $8.9 million, including cash of $8.3 million.
♦  Isradipine was recently launched, and we expect to introduce Hydroxyzine and Dantrolene in the near-term.
♦  We're a penny stock company with eyes on NASDAQ; we need to be Sarbanes Oxley compliant. So we are evaluating the gaps that we have by hiring consultants and external consultants in order to evaluate the checks and      balances we have in order for us to get there.
♦  We are creating infrastructure in our facilities with expanding the facilities and adding new equipment and upgrading the current equipment in order to support our (Eli-200) product launch.
2014 was our best year, 2015 will be the year we file our first ART product, and Q1 2016 will be the year we launch our first ART product and hopefully will be the year we will be on NASDAQ.

Nine-Month Period Ending December 31, 2014
♦  Revenues for the nine months ending December 31, 2014 were $3.8 million, an increase of 6% over revenues for the comparable period of the prior year, even with the one-time milestone being included in the prior year revenues. The increase in revenues is due to the continued growth and expansion of Elite's generic product lines.
♦  During the first nine months of the fiscal year, Elite has invested a total of $9.9 million in product development, including successful completion of the human abuse liability study for ELI-200.




President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.

Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755

Miscellaneous Links:

SEC Filings:

FDA website:

Clinical Trials.Gov:


                                             ELTP Potential Share Price in Relation to Percentage of Pain Market Captured

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ELTP News: Amended Statement of Beneficial Ownership (sc 13d/a) 07/16/2015 04:52:46 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 06/22/2015 02:47:10 PM
ELTP News: Annual Report (10-k) 06/15/2015 04:36:59 PM
ELTP News: Undervalued and Underexposed NYSE-MKT Stock to be Profiled by Large Media Group and four brief reports 06/15/2015 07:00:00 AM
ELTP News: Current Report Filing (8-k) 06/09/2015 01:41:17 PM
#160893  Sticky Note We've launched, what - 8 products... since you Dr Speculator Ninja 08/01/15 12:20:57 PM
#160330  Sticky Note Dianne Will urged me to file SEC Complaint WeeZuhl 07/25/15 09:38:13 AM
#156597  Sticky Note A few more additional FACTS about the Actavis/Epic/Elite Couch 06/11/15 08:13:37 PM
#156231  Sticky Note FOR THOSE WANTING A DEEPER UNDERSTANDING OF WHY Couch 06/09/15 08:10:52 PM
#148487  Sticky Note Ya-don't-say???-Trial-record-1 of-66-for:-eli-200 Drugdoctor 03/21/15 11:04:27 AM
#106205  Sticky Note Elite’s 1st Generation Triple Patents and their Purpose lasers 04/30/14 08:50:54 AM
#161219   More like a "Hail Mary" that slipped one Aqua 08/04/15 10:20:52 PM
#161218   Having common sense and the ability to think Aqua 08/04/15 10:19:02 PM
#161217   Elite can easily leave out Eli 216 and WeeZuhl 08/04/15 10:03:07 PM
#161216   Seems what the joke is here LOL - Couch 08/04/15 09:53:02 PM
#161215   Sort of how we screamed about the novel dr_lowenstein 08/04/15 09:16:19 PM
#161214   Remember what caused that buy light to go NASDAQ2020 08/04/15 09:09:35 PM
#161213   Target a Price went from $0.125 to NASDAQ2020 08/04/15 09:07:20 PM
#161212   I did sell on the last run, couldn't newguy11 08/04/15 08:28:24 PM
#161211   Snup, well said. NH was asked to write Eltp 08/04/15 08:26:00 PM
#161210   Solid list! Thank you sir! mrwrn2010 08/04/15 07:55:48 PM
#161209   Our Ceo is assuring us: snupoled 08/04/15 07:51:56 PM
#161208   Just another green day. NASDAQ2020 08/04/15 07:36:09 PM
#161207   I passed on Purdue also. NASDAQ2020 08/04/15 07:33:20 PM
#161206   Gee i hope no SA article, the stock dr_lowenstein 08/04/15 07:09:10 PM
#161205   Exactly what happened at .125. Why would tomorrow Couch 08/04/15 06:44:28 PM
#161204   I won't either; I'll just hype every minute richme 08/04/15 06:40:51 PM
#161203   Regarding Epic I think what it does is Couch 08/04/15 06:33:57 PM
#161202   Got questions for ELTP's Management?... Then get Mocha Jet 08/04/15 06:24:27 PM
#161201   Couch, Doesn't deal with epic mucks things up for snupoled 08/04/15 06:24:05 PM
#161200   Eltp, I agree. We need meat on the bone snupoled 08/04/15 06:19:34 PM
#161198   That makes a lot of sense. After Eli Couch 08/04/15 05:13:45 PM
#161197   I know someone sold at .125 and bought Chuc 08/04/15 05:07:00 PM
#161196   I guess I started this Epic thing today. Gman24 08/04/15 04:50:40 PM
#161195   You get out in the morning JUST SAYING toybaby 08/04/15 04:46:28 PM
#161194 will tank tomorrow, lots of red.. you dest_golf 08/04/15 04:43:36 PM
#161193   You and me plus many others who have YJ4LIFE 08/04/15 04:40:57 PM
#161192   A logical perspective worth noting. Lock and Aqua 08/04/15 04:32:28 PM
#161191   I will be holding and selling along with him... newguy11 08/04/15 04:30:28 PM
#161190   I guess they sold it up today. Hutch321 08/04/15 04:28:33 PM
#161189   Nasrat has a plan and getting Eli 200 Mocha Jet 08/04/15 04:06:29 PM
#161188   "How is Nasrat going to sell plus 152 YJ4LIFE 08/04/15 04:05:23 PM
#161187   After sitting at the .229 ASK for 45 richme 08/04/15 04:01:40 PM
#161186   Elite has similar technology to Pfizer - better Couch 08/04/15 03:38:58 PM
#161185   Elite has no last laugh until they produce something! richme 08/04/15 03:28:48 PM
#161184   "If there is no interest why did one IB_ 08/04/15 03:28:44 PM
#161183   Since when is trading a buyer seller situation, richme 08/04/15 03:27:17 PM
#161182   MMs usually do for whatever their purpose is. richme 08/04/15 03:25:23 PM
#161181   Seems like a colored flash of GREEN means richme 08/04/15 03:23:50 PM
#161180   Sounds good Eltp 08/04/15 03:20:51 PM
#161179   that was my concern since there is Jimmy Joe 08/04/15 03:18:59 PM
#161178   That's why they call it trading. I have steve9465 08/04/15 03:08:40 PM
#161177   Can they buy Elite out IB? Jimmy Joe 08/04/15 03:07:10 PM
#161176   We shall see Jimmy. I'm sure everyone has Eltp 08/04/15 03:05:34 PM
#161175   They travel to the netherspheres Cosh Dawg 08/04/15 03:04:46 PM
#161174   Epic-Mikah gate? I really dont see anything to Jimmy Joe 08/04/15 03:02:30 PM
#161173   Purdue COULD have what Elite has now, all IB_ 08/04/15 02:59:22 PM
#161172   Ah yes I had forgotten about Purdue, paid YJ4LIFE 08/04/15 02:55:10 PM
#161171   Call Aqua a racist and no apologies. Aqua 08/04/15 02:53:39 PM
#161170   It is not a theory. When someone Hutch321 08/04/15 02:50:39 PM
#161169   Ah yes I had forgotten about Purdue, paid Jimmy Joe 08/04/15 02:49:32 PM